Burning Rock Biotech (BNR) Stock Price, News & Analysis

Company Overview

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS)-based tests designed to support cancer screening, diagnosis, treatment selection and disease monitoring.

Its products and services include tumor profiling and liquid biopsy tests that analyze genetic changes associated with cancer. Burning Rock also provides testing services to hospitals, physicians and biopharmaceutical companies, including services intended to help identify patients for clinical trials and evaluate targeted cancer therapies.

Founded in 2014, Burning Rock is headquartered in Guangzhou, China, and primarily serves the Chinese healthcare and pharmaceutical markets, with additional activities connected to international clinical development. The company was listed on the Nasdaq Global Select Market in 2020. Burning Rock was founded and is led by Yusheng Huang, who serves as chief executive officer.

Key Stats

• Today's Range: $15.08 to $15.26
• 50-Day Range: $8.79 to $14.73
• 52-Week Range: $6.79 to $41.72
• Volume: 1,523 shs
• Average Volume: 26,350 shs
• Market Capitalization: $160.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Burning Rock Biotech Stock Analysis - MarketRank™

Burning Rock Biotech scored higher than 13% of companies evaluated by MarketBeat, and ranked 850th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Burning Rock Biotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Burning Rock Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Burning Rock Biotech is -17.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Burning Rock Biotech is -17.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Burning Rock Biotech has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.52% of the float of Burning Rock Biotech has been sold short.

Short Interest Ratio / Days to Cover

Burning Rock Biotech has a short interest ratio ("days to cover") of 5.02.

Change versus previous month

Short interest in Burning Rock Biotech has recently decreased by 3.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Burning Rock Biotech does not currently pay a dividend.

Dividend Growth

Burning Rock Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Burning Rock Biotech this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $3,023,768.00 in company stock, which represents 1.8805% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Burning Rock Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,023,768.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

30.03% of the stock of Burning Rock Biotech is held by institutions.

Company Calendar

• Last Earnings: 9/10/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNR
• CIK: 1792267
• Web: www.brbiotech.com
• Phone: 86-185-0164-1666
• Fax: N/A
• Employees: 667
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.92 million
• Net Margins: -13.60%
• Pretax Margin: -13.48%
• Return on Equity: -12.98%
• Return on Assets: -8.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.05
• Quick Ratio: 2.90

Sales & Book Value

• Annual Sales: $77.16 million
• Price / Sales: 2.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.28 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 10,520,000
• Free Float: 7,331,000
• Market Cap: $158.63 million
• Optionable: Not Optionable
• Beta: 1.38